US Pharma MarketingMerck didn’t design calderasib to be the most potent KRAS G12C inhibitor on its own. It was designed to be the most combinable inhibitor. Merck didn’t design calderasib to be the most potent KRAS G12C inhibitor on its own. It was designed to be the most combinable inhibitor. The KRAS gene encodes a protein that signals for cell growth. It cycles between active and inactive states, signaling when cells should divide. Although it is one of the most commonly mutated genes across human cancers, it was considered undruggable for decades due to its smooth surface. The G12C mutation locks KRAS…
Merck didn’t design calderasib to be the most potent KRAS G12C inhibitor on its own. It was designed to be the most combinable inhibitor. The KRAS gene encodes a protein that signals for cell growth. It cycles between active and inactive states, signaling when cells should divide. Although it is one of the most commonly…
The post Calderasib’s real innovation: designed for combinability and potency appeared first on Drug Discovery and Development.
Source: Drug Discovery & Development